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Soluble Guanylate Cyclase (sGC) is a heterodimeric heme
containing enzyme of which two active isoforms have
been identified: alpha1beta1 and alpha2beta1. It cata-
lyzes the formation of the intracellular messenger mole-
cule guanosine 3'-5'-cyclic monophosphate (cGMP) from
guanosine 5'-triphosphate (GTP), and is a major effector
protein of the ubiquitous signaling molecule Nitric Oxide
(NO). As such it is an important central mediator in the
NO/cGMP pathway, and is involved in the regulation of a
number of physiological processes such as neurotransmis-
sion, platelet reactivity and particularly smooth muscle
relaxation; thereby regulating blood pressure, gastro-
intestinal motility and genital erection. Dysfunction of
this pathway is involved in the pathogenesis of several dis-
eases.
We chose to use transgenic technology to study the poten-
tial value of the sGC isoforms as drug targets. Besides
obtaining homologous recombinant ES-cells for both a
(conditional) sGCalpha2 knockout and a sGCbeta1H105P
knockin, which can (presumably) no longer be activated
by NO, we were able to obtain sGCalpha1 full and condi-
tional knockouts making use of the Cre/LoxP system. Car-
diovascular phenotyping of these mice showed a gender-
specific hypertension in the male knockouts (see Figure
1), which only appears after 12 weeks of age. This hyper-
tensive phenotype seems very interesting for cardiovascu-
lar medicine, seeing as it reflects the situation in humans
where males are more prone to hypertension and ensuing
cardiovascular accidents as compared to premenopausal
women.
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Gender-specific hypertension in sGCalpha1 knockout miceFigure 1
Gender-specific hypertension in sGCalpha1 knockout mice. 
Blood pressure measurements on male and female wildtype 
(+/+), heterozygous (+/-) and sGCalpha1 knockout (-/-) mice 
of at least 16 weeks old. Male knockout mice are hyperten-
sive (ANOVA: p < 0,0001).
